Vir Biotechnology (VIR) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Vir Biotechnology

NasdaqGS•Healthcare•Biotechnology

$11.39-0.06(-0.01%)Market closed

Market Cap

$1.75B

P/S

5.8x

P/B

1.8x

Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company's preclinical candidates include those targeting influenza A and B antibodies and antibody drug conjugates, and coronavirus monoclonal antibodies; and PRO-XTEN, a dual-masked TCEs targeting variety of solid tumors. It has grant collaboration and license agreement with Astellas; license agreement with Norgine for the treatment of CHD; amended and restated letter agreement with the Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreement with the Institute for Research in Biomedicine; a license agreement with The Rockefeller University; license agreements with Xencor; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

How this company scores

AverageMetricSide Score: 54/100

Strongest: Growth (18/25); weakest: Cash & Earnings Quality (9/25).

Profitability12/25

Growth18/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality9/25

Strengths

Growing revenueInterest easily coveredProfit converts from growthNet cash position

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 6.5x5y range 2.2x – 10.1x

Currently above its 5-quarter median.

P/S · 5.8x5y range 1.1x – 46.4x

Currently below its 20-quarter median.

P/B · 1.8x5y range 0.7x – 6.4x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 7 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $1.75B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $303.23M
Q. Revenue: $238.95M
TTM EBITDA: $-268.76M
TTM Op. Income: $-280.19M
Q. Op. Income: $73.47M
TTM Net Income: $-251.68M
Q. Net Income: $80.08M
EPS: $0.48
Shares Out.: $167.72M

$303.23M in TTM revenue grew 1495.9% YoY, reaching $238.95M last quarter. TTM EBITDA of $-268.76M and TTM operating income of $-280.19M show growth is flowing through to the bottom line. However, net income is negative at $251.68M — growth is not yet reaching the bottom line. Over the past year, TTM revenue is up 1496% — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 100.0%
EBITDA Margin: 31.9%
Op. Margin: 30.7%
Net Margin: 33.5%

Op. margin of 30.7% is up 9785.0% YoY — cost efficiency is improving. Net margin at 33.5% and gross margin of 100.0% show how much of each revenue dollar survives to profit. Over the past year, operating margin is up 100% — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 5.8x
P/B Ratio: 1.8x

P/S of 5.8x and P/B of 1.8x.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $1.21B
Cash: $278.73M
Long-Term Debt: N/A
Book Value: $982.49M
D/E Ratio: N/A
Debt/EBITDA: 0.0

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $123.33M
TTM Free Cash Flow: $-203.59M
FCF Margin: -67.1%
FCF / Net Income: 0.8

TTM FCF of $-203.59M on $123.33M in operating cash flow. The FCF / Net Income ratio of 0.8x means free cash flow covers net income — earnings are backed by cash. Over the past year, free cash flow is up 56% — an improving trend.